Free tool
FAERS Monitor: Retin-A
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019049 or its brand name (Retin-A, Tretinoin). Reports on generic versions are filed under their own applications.
Reports
7,870
Serious
4,782
61% of reports
Hospitalization
1,663
Death reported
883
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use965
- drug ineffective813
- pain586
- product use in unapproved indication509
- vomiting504
- nausea442
- rash434
- headache426
- diarrhoea411
- paraesthesia397
- abdominal pain upper387
- fatigue371
- hypoaesthesia364
- drug intolerance346
- depression344
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 48 |
| 2005 | 48 |
| 2006 | 38 |
| 2007 | 52 |
| 2008 | 135 |
| 2009 | 99 |
| 2010 | 112 |
| 2011 | 159 |
| 2012 | 203 |
| 2013 | 118 |
| 2014 | 178 |
| 2015 | 318 |
| 2016 | 528 |
| 2017 | 478 |
| 2018 | 533 |
| 2019 | 455 |
| 2020 | 445 |
| 2021 | 453 |
| 2022 | 576 |
| 2023 | 646 |
| 2024 | 758 |
| 2025 | 887 |
| 2026 | 603 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,289 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug intoleranceSignal | 346 | 9.6 | 8.7 | 2,661 |
| paraesthesiaSignal | 397 | 6.8 | 6.1 | 1,952 |
| hypoaesthesiaSignal | 364 | 6.5 | 5.9 | 1,701 |
| product use in unapproved indicationSignal | 509 | 5.5 | 5.1 | 1,887 |
| abdominal pain upperSignal | 387 | 5.0 | 4.6 | 1,256 |
| depressionSignal | 344 | 4.0 | 3.6 | 793 |
| off label useSignal | 965 | 2.9 | 2.8 | 1,292 |
| vomitingSignal | 504 | 2.9 | 2.6 | 624 |
| rashSignal | 434 | 2.7 | 2.4 | 458 |
| painSignal | 586 | 2.6 | 2.4 | 567 |
| headache | 426 | 1.8 | 1.7 | 160 |
| diarrhoea | 411 | 1.7 | 1.5 | 122 |
| drug ineffective | 813 | 1.6 | 1.5 | 221 |
| nausea | 442 | 1.5 | 1.4 | 74 |
| fatigue | 371 | 1.3 | 1.2 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.